Welcome! Log into your account
Forgot your password? Get help
Recover your password
A password will be e-mailed to you.
Tag: Johnson & Johnson
WHO Recommends the Use of Bedaquiline Containing Johnson & Johnson’s SIRTURO®
Johnson & Johnson recognizes the World Health Organization (WHO)’s Rapid Communication indicating that all-oral regimens containing Johnson & Johnson’s SIRTURO® (bedaquiline) are the preferred...
Auris Health Publish Results from Monarch™ Platform
Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, announced results from a study demonstrating the safety and feasibility of the Monarch Platform, a first-of-its-kind roboti...
Actelion Pharma Announced Data Evaluating Combination Therapy with OPSUMIT® and TadalafIl
Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, announces new data evaluating initial combination therapy with OPSUMIT® (macitentan) and tadalafIl, a PDE5 inhi...
Johnson & Johnson and Teva Ready to Pay to Settle Opioid Litigations
Johnson & Johnson has offered to pay $4 billion to settle all claims accusing the company of helping fuel the U.S. opioid epidemic, as part of a potentially larger deal involving drugmakers and di...
Court Ordered Johnson & Johnson to Pay $8bn
Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could gr...
Johnson & Johnson Dedicated $500m to Eliminate HIV and Tuberculosis by 2030
Johnson & Johnson announced that it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accele...
J&J Announced Agreement with Ohio Counties Ahead of Upcoming Opioid Trial
Johnson & Johnson and its Janssen Pharmaceutical Companies announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties’ claims with no admissio...
J&J Stelara Approved in EU for Ulcerative Colitis
Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared...
J&J Announced Launch of Consortium to Discover and Develop New TB Antibiotics
As part of the Company’s 10-year initiative to drive progress against tuberculosis (TB), Johnson & Johnson announced that it has launched an international research consortium to discover and devel...
U.S. Justice Department Pursue Investigation over Cancer Risk in J&J’s Powder
The U.S. Justice Department is pursuing a criminal investigation into whether Johnson & Johnson lied to the public about the possible cancer risks of its talcum powder, people with knowledge of th...
Celsius and Janssen in Collaboration
Celsius Therapeutics announced a collaboration with Janssen Biotech. Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify...
Johnson & Johnson Announced Results from the Phase 3 Study of XARELTO®
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivar...
J&J’s INVOKANA Significantly Reduced Major Cardiovascular Events and Kidney Failure
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of a new subgroup analysis from the landmark phase 3 CREDENCE study, showing INVOKANA® (canagliflozin) significantly red...
J&J Published Data from Phase 3 DARZALEX® Study
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of data from the randomized, open-label Phase 3 MAIA (MMY3008) study that showed DARZALEX® (daratumumab) plus le...
J&J Used Underhanded Tactics to Fend Off Generics
Johnson & Johnson’s blockbuster cancer med Zytiga only recently lost its shield against generic competition, and according to a new lawsuit, that’s because J&J used underhanded tactics to ke...
J&J Presented Early Results from First-In-Human Study of Monarch™ Platform
Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, announced early positive results from an ongoing study designed to evaluate the safety and feasibility of the Monarch Platf...
Page 1 of 3
Pharmasyntez Group of Companies
Rafarma – a full cycle pharmaceutical enterprise
Binnopharm – full-cycle biopharmaceutical faciliti...
Pharmacor Production Ltd.
EXCELLENCE IN OLEOCHEMICAL EXCIPIENTS AND APIs
Active pharmaceutical substance for preparation of sterile and non-sterile drug products
Suitable for pharmaceutical oral & infusion formulations
Made in Germany
TOP 30 Pharmaceutical Contract Manufacturing Organisations
EAEU May Allow to Register Empty Primary Packages as Medical...
GMP Inspection Practice: a Case for Global Benchmarking, Con...
Regulation of Autogenous Vaccines
Inspection of Foreign Manufacturers of Veterinary Products
FDA Approved XCOPRI to Treat Partial-Onset Seizures
Subscribe to Newsletter!
© GMP news